BSD Medical sells hyperthermia systems to a U.S. Government medical facility

NewsGuard 100/100 Score

BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that a U.S. Government medical facility has purchased a BSD-500 Hyperthermia System (BSD-500). "BSD has received purchase orders for eight hyperthermia systems since September 1, 2010, the beginning of BSD's 2011 fiscal year," stated Harold Wolcott, BSD's President. "Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. We are excited that this technology will be more widely available to patients throughout the world."

“BSD has received purchase orders for eight hyperthermia systems since September 1, 2010, the beginning of BSD's 2011 fiscal year”

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Certain progestogens linked to higher brain tumor risk in women, study suggests